Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology

DOI 10.1016/s0090-4295(97)00459-7

Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.129 · Cited by 281
The association of benign prostatic hyperplasia and cancer of the prostate
Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. T., & Murphy, G. P. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+ · Cited by 222
Early Detection of Prostate Cancer
Scardino, P. T. (1989) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01800-0 · Cited by 210
Quality of Life and Functional Status Measures in Patients With Head and Neck Cancer
DʼAntonio, L. L., Zimmerman, G. J., Cella, D. F., & Long, S. A. (1996) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1996.01890170018005 · Cited by 197
Self-citation

Show all 22 references

Research works printed but not linked: 2

da Silva, 1993, Quality of life in patients with prostatic cancer. A feasibility study, Cancer, 71, 1138, 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7 · DOI
Esper, 1995, FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract), J Urol, 153

Sorted by citations

Items 401–500 of 696

Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite
Lee, T. K., Poon, D. M. C., Ng, A. C. F., Ho, T., Singh‐Carlson, S., Joffres, M., Oshan, G., Kohli, J., & Kwan, W. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12855 · Cited by 12
Investigating the relationships between quality of life, fatigue and leisure time physical activity in prostate cancer patients
Özdemir, K., Keser, İ., Şen, İ., & Tan, M. Ö. (2018) · Journal of Back and Musculoskeletal Rehabilitation · doi:10.3233/bmr-181220 · Cited by 12
“PCa speciﬁc QoL questionnaires generally include physical, social and/or family status, functional well-being and information about additional concerns spe-ciﬁc to PCa [22].”
Health-Related Quality of Life and Its Associated Factors in Prostate Cancer Patients Who Receive Androgen Deprivation Therapy
Chien, C., Chuang, C., Liu, K., Wu, C., Pang, S., & Chang, Y.-H. (2019) · Cancer Nursing · doi:10.1097/ncc.0000000000000752 · Cited by 12
Quality of life among men treated with radiation therapy for prostate cancer.
Ward-Smith, P. A., & Kapitan, D. (2005) · PubMed · Cited by 12
Prostate Cancer Treatment and Quality of Life
Prezioso, D., Galasso, R., Martino, M. D., & Iapicca, G. (2007) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-40901-4_15 · Cited by 12
Quality-of-life concerns in lung cancer patients
Siddiqui, F., Konski, A. A., & Movsas, B. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.81 · Cited by 12
Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity
Curigliano, G., de Braud, F., Sandri, M. T., Renne, G., Zorzino, L., Scardino, E., Rocco, B. M. C., Spitaleri, G., Pas, T. M. D., Noberasco, C., et al. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328136c162 · Cited by 12
Measuring Quality of Life Following Robot-Assisted Radical Prostatectomy
Hale, G. R., Shahait, M., Lee, D. I., Lee, D. J., & Dobbs, R. W. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s271447 · Cited by 11
Cancer de la prostate et relation conjugale : point de vue du patient et de sa conjointe. Résultats préliminaires
Lafaye, A., Cousson‐Gélie, F., Petit, S., & Bouisson, J. (2007) · Psycho-Oncologie · doi:10.1007/s11839-007-0056-7 · Cited by 11
A systematic review of tools used to assess body image, masculinity and self‐esteem in men with prostate cancer
Bowie, J., Brunckhorst, O., Stewart, R. J., Prokar Dasgupta, A., & Ahmed, K. (2020) · Psycho-Oncology · doi:10.1002/pon.5518 · Cited by 11
Phase I/II Study of Weekly Docetaxel and Vinblastine in the Treatment of Metastatic Hormone-Refractory Prostate Carcinoma
Tester, W. J., Ackler, J. R., Tijani, L., & Leighton, J. K. (2006) · The Cancer Journal · doi:10.1097/00130404-200607000-00008 · Cited by 11
Assessing Quality of Life
Penson, D. F., & Litwin, M. S. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-714-7_10 · Cited by 11
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
Sandhu, S., Joshua, A. M., Emmett, L., Bressel, M., Anton, A., Spain, L., Horvath, L. G., Pasam, A., Tolmeijer, S. H., Akhurst, T., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00017-3 · Cited by 13
Testing the efficacy of a couple-focused, tailored eHealth intervention for symptom self-management among men with prostate cancer and their partners: the study protocol
Song, L., Nielsen, M. E., Chen, R. C., Rini, C. K., Keyserling, T. C., Idiagbonya, E., Fuller, G. P., Northouse, L., Palmer, M. H., & Tan, X. M. (2022) · Trials · doi:10.1186/s13063-021-05948-5 · Cited by 10
Evaluation of sexual function after robot‐assisted radical prostatectomy: A farewell to IIEF questionnaire
Shiraishi, K. (2023) · International Journal of Urology · doi:10.1111/iju.15264 · Cited by 10
Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)
Brown, M., MURPHY, M. H., McAneney, H., McBride, K., Crawford, F., Cole, A., O’Sullivan, J. M., Jain, S., & Prue, G. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07894-1 · Cited by 11
“The FACT-P is a 39-item HRQoL questionnaire assessing five domains (physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns) in the previous 7 days, with higher scores indicating improved quality of life [38].”
Background
Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review
Schmid, S., Omlin, A. G., Blum, D., Strasser, F., Gillessen, S., & Rothermundt, C. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv326 · Cited by 10
Higher-intensity exercise helps cancer survivors remain motivated
Martin, E., Battaglini, C. L., Hands, B. P., & Naumann, F. (2015) · Journal of Cancer Survivorship · doi:10.1007/s11764-015-0498-z · Cited by 12
Associations of light physical activity, moderate-to-vigorous physical activity and sedentary behavior with quality of life in men on androgen deprivation therapy for prostate cancer: a quantile regression analysis
Trinh, L., Alibhai, S. M. H., Culos-Reed, N. S., Sabiston, C. M., Jones, J. M., Rosenberg, D. E., Whitehorn, A., Bastas, D., & Faulkner, G. (2022) · Journal of Behavioral Medicine · doi:10.1007/s10865-022-00285-7 · Cited by 10
Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer
Kim, S., Kong, J. H., Lee, Y., Lee, J. Y., Kang, T. W., Kong, T. H., Kim, M. H., & You, S. H. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012817.pub2 · Cited by 10
Pre- and Post-Radiotherapy Sexual Functioning in Prostate Cancer Patients
Monga, U., Kerrigan, A. J., Garber, S. L., & Monga, T. N. (2001) · Sexuality and Disability · doi:10.1023/a:1017901224691 · Cited by 10
“Functional Assessment of Cancer Therapy for Prostate (FACT-P) (12, 13 ),”
Background
Desarrollo y validación del primer cuestionario español de calidad de vida en pacientes con cáncer de próstata, basado en la percepción del paciente
Veiga, F. G., Cozar, M. J. O., Günthner, S., Pallás, M. P., Moyano, A. S., Ramos, E. B., & Rebollo, J. F. (2009) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(09)74200-7 · Cited by 10
Qualité de vie après radiothérapie pour un cancer localisé de la prostate
Joly, F., Degrendel, A.-C., & Guizard, A. (2010) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2010.06.015 · Cited by 10
Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients
Bremner, K. E., TOMLINSON, G. A., & Krahn, M. D. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9264-7 · Cited by 10
“FACT-P, Functional Assessment of Cancer Treatment—Prostate, Version 2 is a psychometric instrument on which scores can range from 0 to 160, with higher score indicating better quality of life [42, 43 ] 1670 Qual Life Res (2007) 16:1665–1675”
BackgroundMethodInfluential
Patient-Reported Toxicity Correlated to Dose–Volume Histograms of the Rectum in Radiotherapy of the Prostate
Taussky, D., Schneider, U., Rousson, V., & Pescia, R. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000091355.26165.81 · Cited by 10
Prostate Cancer: A Chronic Illness
Doyle-Lindrud, S. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.857-861 · Cited by 11
The impact of combining human and online supportive resources for prostate cancer patients
Hawkins, R. P. (2017) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0330 · Cited by 10
Quality of life in home-dwelling cancer patients aged 80 years and older: a systematic review
Hjelmeland, I. H. H., Drageset, J., Nordvik, Ø., & Beisland, E. G. (2022) · Health and Quality of Life Outcomes · doi:10.1186/s12955-022-02070-1 · Cited by 9
Examining the impact of androgen deprivation therapy, masculine self‐esteem, and psychological flexibility on distress and quality of life in men with prostate cancer
Chowdhury, E., Horrocks, T., McAteer, G., & Gillanders, D. T. (2024) · Psycho-Oncology · doi:10.1002/pon.6277 · Cited by 11
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
TOMBAL, B. F., Freedland, S. J., Armstrong, A. J., Beer, T. M., Stenzl, A., Sternberg, C. N., Hussain, M., Ganguli, A. X., Ramaswamy, K., Bhadauria, H. S., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00447-9 · Cited by 10
A Systematic Review to Evaluate Patient-Reported Outcome Measures (PROMs) for Metastatic Prostate Cancer According to the COnsensus-Based Standard for the Selection of Health Measurement INstruments (COSMIN) Methodology
Ratti, M. M., Gandaglia, G., Sisca, E. S., Derevianko, A., Alleva, E., Beyer, K., Moss, C. L., Barletta, F. M., Scuderi, S., Omar, M. I., et al. (2022) · Cancers · doi:10.3390/cancers14205120 · Cited by 9
Effects of androgen deprivation on white matter integrity and processing speed in prostate cancer patients.
Chaudhary, S., Roy, A. M., Summers, C., Ahles, T. A., Li, C. R., & Chao, H. H. (2022) · PubMed Central · Cited by 9
A powerful partnership: researchers and patients working together to develop a patient-facing summary of clinical trial outcome data
Ruzich, E., Ritchie, J., Sowell, F. G., Mansur, A., Griffiths, P., Birkett, H., Harman, D., Spink, J., James, D., & Reaney, M. D. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad099 · Cited by 9
“…relevance of six different PRO data concepts (aligned with COU-AA-302 and using the Functional Assessment of Cancer Therapy-Prostate [FACT-P], 26 a standard PRO assessment tool implemented in PC clinical trials: social/family well-being, emotional well-being, functional well-being, physical…”
Method
EVALUATION OF UTILITY INDEX OF QUALITY OF LIFE (QOL) IN PROSTATE CANCER PATIENTS: COMPARISON OF QOL UTILITY INDEX EuroQol-5D (EQ-5D) AND VISUAL ANALOGUE SCALE (VAS) WITH HEALTH-RELATED QOL QUESTIONNAIRES SF-36 AND EPIC
Akakura, K., Matsuzaki, K., Kobayashi, T., Kitoh, H., Mizoguchi, K., Tomikawa, G., Takura, T., & Kawabuchi, K. (2011) · The Japanese Journal of Urology · doi:10.5980/jpnjurol.102.9 · Cited by 9
Cuestionario Español de Calidad de Vida en Pacientes con Cáncer de Próstata como medida de la calidad de vida de los pacientes con cáncer de próstata en España: aplicación a la actividad diaria
Gómez-Veiga, F., Cozar, J. M., Günthner, S., Pallás, M. P., Silmi-Moyano, A., & Rebollo, F. J. (2010) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2010.05.001 · Cited by 9
USE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002–15
Torvinen, S., Bergius, S., Roine, R. P., Lodenius, L., Sintonen, H., & Taari, K. (2016) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462316000118 · Cited by 9
Quality of life in active surveillance and the associations with decision-making—a literature review
Menichetti, J., Valdagni, R., & Bellardita, L. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2017.12.34 · Cited by 9
“Other QoL measures were the Functional Assessment of Cancer TherapyProstate (29) (n=2 studies), the UCLA Prostate Cancer Index (30) (n=1 study), and the EORTC QLQ-C30 (31) (n=1 study).”
Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review
Marandino, L., Vignani, F., Buttigliero, C., Gamba, T., Necchi, A., Tucci, M., & Maïo, M. D. (2020) · Cancers · doi:10.3390/cancers12092568 · Cited by 10
Hypothalamic connectivities predict individual differences in ADT-elicited changes in working memory and quality of life in prostate cancer patients
Chaudhary, S., Roy, A. M., Summers, C., Zhornitsky, S., Ahles, T. A., Li, C.-S. R., & Chao, H. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-13361-4 · Cited by 9
Health‐related quality of life after carbon‐ion radiotherapy for prostate cancer: A 3‐year prospective study
Katoh, H., Tsuji, H., Ishikawa, H., Kamada, T., Wakatsuki, M., Hirasawa, N., Suzuki, H., Akakura, K., Nakano, T., Shimazaki, J., et al. (2013) · International Journal of Urology · doi:10.1111/iju.12294 · Cited by 9
Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer
Bruner, D. W., Hanlon, A. L., Mazzoni, S., Raysor, S. L., Konski, A. A., Hanks, G. E., & Pollack, A. S. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)01434-2 · Cited by 9
Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer
Miwa, S., Mizokami, A., Konaka, H., Ueno, S., Kitagawa, Y., Koh, E., & Namiki, M. (2013) · Prostate International · doi:10.12954/pi.13021 · Cited by 9
Patient‐reported outcome measures in metastatic prostate cancer
Sellers, L., Savas, A. N., Davda, R., Ricketts, K., & Payne, H. A. (2016) · Trends in Urology & Men s Health · doi:10.1002/tre.504 · Cited by 9
Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
Suttmann, H., Gleißner, J., Huebner, A., Mathes, T., Baurecht, W., Krützfeldt, K., Sweiti, H., & Feyerabend, S. (2020) · Cancers · doi:10.3390/cancers12092550 · Cited by 9
Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
Chung, D. Y., Ha, J. S., & Cho, K. S. (2021) · Biomedicines · doi:10.3390/biomedicines9060661 · Cited by 9
Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types
King‐Kallimanis, B. L., Lederer, N. M., Kim, J., Nair, A., Horodniceanu, E. G., Bhatnagar, V., & Kluetz, P. G. (2021) · Value in Health · doi:10.1016/j.jval.2021.04.1279 · Cited by 9
Measuring self-reported sexual function in men with prostate cancer
Brucker, P. S., & Cella, D. F. (2003) · Urology · doi:10.1016/s0090-4295(03)00514-4 · Cited by 9
Self-citation
Quality of life following prostate cancer treatments
Penson, D. F. (2000) · Current Urology Reports · doi:10.1007/s11934-000-0038-9 · Cited by 9
“The FACT-P contains 38 items, each of which contains a statement that the patient may agree or disagree with across a five-point spectrum [ 9 ].”
Background
An evidence-based approach to prostate cancer follow-up
Yao, S., & DiPaola, R. S. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00099-x · Cited by 9
Familism, family cohesion, and health-related quality of life in Hispanic prostate cancer survivors
Pedreira, P. B., Fleszar‐Pavlović, S. E., Walsh, E. A., Esquives, B. S. N., Moreno, P. I., Perdomo, D. M., Heller, A. S., Antoni, M. H., & Penedo, F. J. (2024) · Journal of Behavioral Medicine · doi:10.1007/s10865-024-00479-1 · Cited by 8
“The Functional Assessment of Cancer Therapy – General (FACT-G) was used to measure general HRQoL (Bonomi et al., 1996; Cella et al., 1993; Esper et al., 1997).”
The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Stenzl, A., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J. M., Villers, A. A., Azad, A., Alcaraz, A., Alekseev, B. Y., Iguchi, T., Shore, N. D., et al. (2022) · The Prostate · doi:10.1002/pros.24396 · Cited by 8
Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Ito, T., Grant, L., Duckham, B. R., Ribbands, A., & Gater, A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0825-7 · Cited by 8
A drug safety evaluation of enzalutamide to treat advanced prostate cancer
Fred Saad, C., Hamilou, Z., & Lattouf, J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1919620 · Cited by 8
Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge
Massoeurs, L., Ilie, G., Lawen, T., MacDonald, C., Bradley, C., Vo, J. D. C.-T., & Rutledge, R. D. H. (2021) · Current Oncology · doi:10.3390/curroncol28050334 · Cited by 10
“For all sub-domains and total scores, greater scores indicated greater well-being and greater quality of life [31].”
Background
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Rencsok, E. M., Slopen, N. B., McManus, H. D., Autio, K. A., Morgans, A. K., McSwain, L., Barata, P. C., Cheng, H. H., Dreicer, R., Gerke, T. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0446 · Cited by 8
The impact of clinical and sociodemographic features on quality of life in patients with early stage cancers using the Functional Assessment of Cancer Therapy-General assessment tool
Popovic, M. M., Lao, N., Zeng, L., Zhang, L., Cella, D. F., Beaumont, J. L., Chow, R., Chiu, N., Chiu, L., Lam, H., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1789-4 · Cited by 9
Self-citation
Salud y calidad de vida en urología: Aspectos en urología general y oncológica
Heldwein, F. L., Sánchez-Salas, R., Sánchez-Salas, R., Telöken, P., Telöken, C., Castillo, O., & Vallancien, G. (2009) · Archivos Españoles de Urología · doi:10.4321/s0004-06142009000700001 · Cited by 8
The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial
Sheill, G., Brady, L., Guinan, E. M., Hayes, B. D., Casey, O. M., Greene, J. P., Vlajnic, T., Cahill, F., Hemelrijck, M. V., Peat, N., et al. (2017) · Trials · doi:10.1186/s13063-017-2201-3 · Cited by 8
Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers
Wong, R. L., & Morgans, A. K. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0890-3 · Cited by 8
Examining health-related quality of life in men treated for prostate cancer
Litwin, M. S. (1999) · World Journal of Urology · doi:10.1007/s003450050134 · Cited by 8
“It is a 12-item scale that addresses weight loss, appetite, and urinary and erectile diculties [36].”
BackgroundMethod
Assessing the Impact of the Prostate Cancer Patient Empowerment Program (PC-PEP) on Relationship Satisfaction, Quality of Life, and Support Group Participation: A Randomized Clinical Trial
Burgher, C., Ilie, G., Mason, R. J., Rendon, R. A., Kokorovic, A., Bailly, G. G., Patil, N., Bowes, D., Wilke, D., MacDonald, C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100479 · Cited by 7
“Health-related quality of life was assessed using the Functional Assessment of Cancer Therapy–Prostate (FACT-P) questionnaire [21].”
Method
Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
Quintela, M. L., León‐Mateos, L., Estévez, S. V., Calvo, O. F., Anido, U., Afonso, F. J. A., Santomé, L., & Aparicio, L. A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.006 · Cited by 7
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
Blome, C., Augustin, M., Metin, H., & Lohrberg, D. (2016) · The European Journal of Health Economics · doi:10.1007/s10198-016-0765-6 · Cited by 7
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
TOMBAL, B. F., Stenzl, A., Cella, D. F., Loriot, Y., Armstrong, A. J., Fizazi, K. S., Beer, T. M., Sternberg, C. N., Hussain, M., Ivanescu, C., et al. (2021) · Cancers · doi:10.3390/cancers13235872 · Cited by 7
“HRQoL is influenced by disease symptoms, number and types of treatments used (and accompanying adverse events (AEs)) and evolving comorbidities [8].”
BackgroundSelf-citation
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
Tree, A. C., Griffin, C. L., Syndikus, I., Birtle, A. J., Choudhury, A., Graham, J., Ferguson, C., Khoo, V. S., Malik, Z., O’Sullivan, J. M., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.160 · Cited by 7
Docetaxel‐based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival
Nayyar, R., Sharma, N., & Gupta, N. P. (2009) · International Journal of Urology · doi:10.1111/j.1442-2042.2009.02351.x · Cited by 7
Sexual quality of life for localized prostate cancer: a cross‐cultural study between Japanese and American men
Namiki, S., & Arai, Y. (2011) · Reproductive Medicine and Biology · doi:10.1007/s12522-011-0076-7 · Cited by 7
Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases
Desax, M.-C., Hundsberger, T., Rothermundt, C. A., Omlin, A. G., & Gillessen, S. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.04.007 · Cited by 7
Considerations of Cost-Effectiveness for New Radiation Oncology Technologies
Mills, M. D., Spanos, W. J., & Esterhay, R. J. (2006) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2005.12.007 · Cited by 7
“What if…”: Decisional Regret in Patients who Discontinued Active Surveillance
Repetto, C., Rancati, T., Magnani, T., Alvisi, M. F., Avuzzi, B., Badenchini, F., Marenghi, C., Stagni, S., Maffezzini, M., Villa, S., et al. (2016) · Tumori Journal · doi:10.5301/tj.5000564 · Cited by 7
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry
Stenner, F., Rothschild, S. I., Betticher, D. C., Caspar, C. B., Morant, R., Popescu, R. A., Rauch, D., Huber, U., Zenhäusern, R., Rentsch, C. A., et al. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.08.003 · Cited by 7
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
Bianchi, S., Mosca, A., Volta, A. D., Prati, V., Ortega, C., Buttigliero, C., Fea, E., Vanella, P., Valcamonico, F., Zamparini, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.034 · Cited by 7
Statistical issues in the application of cancer outcome measures
Sloan, J. A. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545856.018 · Cited by 7
Quality of life studies and genito-urinary tumors
Bertetto, O., Sergio Bracarda, A., Tamburini, M., & Cortesi, E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_3.s43 · Cited by 7
“Sensitivity to change in performance status and PSA score over a two-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change [33].”
Background
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol
Spratt, D. E., Dorff, T. B., McKay, R. R., Lowentritt, B. H., Fallick, M. L., Gatoulis, S. C., Flanders, S. C., & Ross, A. E. (2024) · Future Oncology · doi:10.2217/fon-2023-0748 · Cited by 6
Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals
Ndlovu, H., Mokoala, K. M. G., Lawal, I. O., Emmett, L., & Sathekge, M. M. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.003 · Cited by 6
Androgen deprivation increases frontopolar cortical thickness in prostate cancer patients: an effect of early neurodegeneration?
Chaudhary, S. (2024) · American Journal of Cancer Research · doi:10.62347/wola8904 · Cited by 6
“As a general measure of QoL, participants completed the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire at baseline and at 6-month follow-up [54, 55].”
Resistance training for fatigue in people with cancer
Ernst, M., Wagner, C., Oeser, A., Messer, S., Wender, A., Cryns, N., Bröckelmann, P. J., Holtkamp, U., Baumann, F. T., Wiskemann, J., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015518 · Cited by 11
Validación en España del cuestionario de calidad de vida PROSQOLI en pacientes con cáncer de próstata avanzado
Fernández-Arjona, M., la Cruz, G. D., Delgado, J. A., Malet, J., & Portillo, J. A. (2012) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2011.11.011 · Cited by 6
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
Luo, J., & Graff, J. N. (2016) · Research and Reports in Urology · doi:10.2147/rru.s104789 · Cited by 6
Quality of life outcomes after low dose‐rate brachytherapy for localized prostate cancer: Current status and future perspectives
Murakami, Y., Satoh, T., Tsumura, H., Tabata, K., Matsumoto, K., Ishiyama, H., & Iwamura, M. (2019) · International Journal of Urology · doi:10.1111/iju.14090 · Cited by 6
Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
Yang, X., Chen, H., Xu, D., Chen, X., Li, Y., Tian, J., Wang, D., & Pang, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09276-y · Cited by 6
Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
Bhole, R. P., Karche, P. M., Gurav, S. S., & Chikhale, R. V. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101143 · Cited by 7
Educational Needs for Sexual Health and Its Effect on Depression and the Quality of Life in Patients with Prostate Cancer
Oh, S., & Ryu, E. (2015) · Asian Oncology Nursing · doi:10.5388/aon.2015.15.3.163 · Cited by 6
Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer
Wyatt, G. K., Sikorskii, A. E., Safikhani, A., McVary, K. T., & Herman, J. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2015.12.315 · Cited by 6
Quality of life before and after prostatectomy as treatment for localized cancer.
Ward-Smith, P. A., & Mehl, J. (2007) · PubMed · Cited by 6
Treatment Registry for Outcomes in Patients with Castration-Resistant Prostate Cancer (TRUMPET): A Methodology for Real-World Evidence and Research
Penson, D. F., Lin, D. W., Karsh, L. I., Quinn, D. I., Shevrin, D. H., Shore, N. D., Symanowski, J. T., Brown, B. A., Forer, D., Wong, E. K., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0298 · Cited by 6
Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
El-Amm, J., Nassabein, R. M., & Aragon‐Ching, J. B. (2017) · Cancer Management and Research · doi:10.2147/cmar.s139305 · Cited by 6
Knowledge and Attitudes Regarding Surgical Castration in Men Receiving Androgen Deprivation Therapy for Metastatic Prostate Cancer and Their Relationship to Health-Related Quality of Life
Schubbe, M. E., Gellhaus, P. T., Tobert, C. M., Mott, S. L., Garje, R., & Erickson, B. A. (2021) · Urology · doi:10.1016/j.urology.2021.04.027 · Cited by 6
A prospective longitudinal study to evaluate bone health, implication of FRAX tool and impact on quality of life (FACT-P) in advanced prostate cancer patients.
Sharma, A., Garg, G., Sadasukhi, N., Sadasukhi, T. C., Gupta, H. L., Gupta, M., Malik, S., Patel, K., & Sinha, R. J. (2021) · PubMed Central · Cited by 6
[The incidence of internal parasites in dogs and cats as dependent on the level of awareness among owners].
Michalczyk, M., & Sokół, R. (2008) · PubMed · Cited by 6
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
Procopio, G., Chiurì, V. E., Giordano, M., Alitto, A. R., Maisano, R., Bordonaro, R., Cinieri, S., Rossetti, S., Placido, S. D., Airoldi, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100431 · Cited by 6
“18 The questionnaire includes the 27-item FACT d general (FACT-G) questionnaire [4 domains, i.e. physical (7 items), social or family (7 items), emotional (6 items), and functional well-being (7 items)], which measures HRQoL in cancer patients, and a 12-item prostate cancer subscale, designed to…”
Method
Evidence from clinical trials for the use of valproic acid in solid tumors: focus on prostate cancer
Goyal, J., & Rodríguez, R. (2013) · Clinical Investigation · doi:10.4155/cli.13.23 · Cited by 6
Quality of Life in Patients with Advanced Cancer Using the Functional Assessment of Cancer Therapy-General Assessment Tool: A Literature Review
Popovic, M. M. (2013) · World Journal of Oncology · doi:10.4021/wjon594w · Cited by 6
Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)
Brown, M., MURPHY, M. H., McDermott, L., McAneney, H., O’Sullivan, J. M., Jain, S., & Prue, G. (2019) · Pilot and Feasibility Studies · doi:10.1186/s40814-019-0486-6 · Cited by 6
Quality of life after treatment for prostate cancer
Penson, D. F., & Litwin, M. S. (2003) · Current Prostate Reports · doi:10.1007/s11918-003-0009-y · Cited by 6
Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib
Curigliano, G., Spitaleri, G., COBELLI, O. D., Scardino, E., Sbanotto, A., & de Braud, F. (2009) · Urologia Internationalis · doi:10.1159/000200800 · Cited by 6
“QoL was assessed on a 3-point scale (good, fair, poor), pain score and analgesic consumption were assessed daily by visual analogue scale (VAS) as recorded in a patient diary, and monthly pain intensity was assessed using the McGill-Melzack questionnaire [”
Opportunities and Challenges: Assessing Quality of Life in Clinical Trials
Giesler, R. B., & Williams, S. D. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1498 · Cited by 6
Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study
Murthy, V., Kimura, K., Theus, L., Nguyen, A., Grogan, T., Lokre, O., Perk, T., Rettig, M. B., Drakaki, A., Shen, J., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270916 · Cited by 5
“Patients completed 3 questionnaires on the same day of each 177 Lu-PSMA-617 cycle: the Functional Assessment of Cancer Therapy – Prostate (FACT-P), the Brief Pain Inventory – Short Form (BPI-SF), and a xerostomia questionnaire (supplemental materials) ( 14 – 16 ).”
Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men’s Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance])
Parsons, J. K., Zahrieh, D., Patel, D. N., Mohler, J. L., Chen, R. C., Paskett, E. D., Liu, H., Peil, E. S., Rock, C. L., Hahn, O. M., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.03.007 · Cited by 5

Authors: Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations: Rush University Medical Center (US)
Corresponding author: Esper, Peg
ORCID: Cella, David
Pienta, Kenneth J.
Venue: Urology
Publisher: Elsevier BV
Published: 1997-12
Volume: 50
Issue: 6
Pages: 920-928
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(97)00459-7
OpenAlex: W2004909463
Cited by: 696
References: 22
Citations by year: 2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI: 4.00
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms: Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks